Soujanya Ravi, Author at PharmaDeviceNews

Why FDA alignment could move Alterity’s ATH434 closer to a pivotal MSA test

Find out how FDA alignment on ATH434 could shape Alterity Therapeutics’ pivotal Phase 3 path in multiple system atrophy.

Find out how TG Therapeutics’ BRIUMVI data could shape a new maintenance strategy in myasthenia gravis treatment.

Ebglyss gains an every-eight-week FDA maintenance option, raising new questions for atopic dermatitis biologic competition.

Find out how FDA approval for Gilead Sciences’ Hepcludex could reshape chronic hepatitis delta virus treatment in the U.S.

Find out how United Therapeutics’ FDA-cleared UHeart trial could reshape xenotransplantation for end-stage heart failure patients.

Find out how MAIA Biotechnology’s ateganosine trials could shape the next phase of lung cancer drug development today.

Find out how Afrezza’s pediatric FDA approval could change mealtime insulin use for children with diabetes and MannKind’s growth story.

Find out how Tempus’ tumor-only xT CDx FDA approval could expand precision oncology testing and reshape solid tumor profiling.

Find out how Pharming’s Joenja sNDA resubmission could reopen the FDA pathway for younger children with APDS.

Find out how Gilead Sciences’ Livdelzi trial data could reshape PBC treatment goals and strengthen the case for ALP normalization.